Please login to the form below

Not currently logged in
Email:
Password:

J&J to aquire Cougar

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission to purchase all outstanding shares

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission (SEC) to purchase all outstanding shares in Cougar Biotechnology. It reported its intent to acquire the Los Angeles-based biotech company in May this year.

Courgar's board of directors has unanimously approved the merger and, if the deal closes successfully, shareholders will receive $43 per share. The company in-licenses and develops clinical stage oncology drugs and currently has products in trials for prostate cancer, breast cancer, multiple myeloma and solid tumours.

The transaction is expected to close during the third quarter of 2009 and is subject to various conditions.

8th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics